BioWorld

Jan. 24, 2005

View Archived Issues

Amylin Publicly Raises $176M To Fund Symlin, Exenatide Plans

Mutations In Mitochondrion Affect Prostate Cancer Risk

Schering-Plough Plans Buyout Of Platform Firm NeoGenesis

Chelsea Joins With Ivory Capital, Goes Public Via Reverse Merger

ViaCell Prices At Low End, But Gets $52.5M In 2005's First IPO

Other News To Note

Ambit Hits A Triple, Signs BMS, GSK, Pfizer To Deals

Ambit Biosciences Inc.'s super-multi-tasking approach to kinase screening bagged the company deals with three of pharma's top players - Bristol-Myers Squibb Co., GlaxoSmithKline plc and Pfizer Inc. (BioWorld Today) Read More

Today's news in brief

BioWorld

BioWorld briefs for Jan 23, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 23, 2026.

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...

Illustration of magnifying glass inspecting brain

Neurotrimin unveiled as marker in intellectual disability

BioWorld Science

Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...